


## CLAIMS

1. A compound of formula (I):



(I)


5

wherein:

- A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocyclyl ring, or an optionally substituted bicyclic heterocyclyl group;
- 10 B represents a phenyl or pyridyl ring;
- Z represents O, S, SO, or SO<sub>2</sub>;
- R<sup>1</sup> represents CO<sub>2</sub>H, CN, CONR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>CO<sub>2</sub>H, optionally substituted SO<sub>2</sub>alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>CONR<sup>5</sup>R<sup>6</sup>, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocyclyl;
- 15 R<sup>2a</sup> and R<sup>2b</sup> each independently represents hydrogen, halo, optionally substituted alkyl, optionally substituted alkoxy, CN, SO<sub>2</sub>alkyl, SR<sup>5</sup>, NO<sub>2</sub>, optionally substituted aryl, CONR<sup>5</sup>R<sup>6</sup> or optionally substituted heteroaryl;
- R<sup>x</sup> represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally substituted by a group independently selected from NR<sup>4</sup>, O and SO<sub>n</sub>,
- 20 wherein n is 0, 1 or 2; optionally substituted alkenyl; or optionally substituted alkynyl; or R<sup>x</sup> represents optionally substituted alkenyl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-heterocyclyl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-bicyclic heterocyclyl or optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-aryl;
- R<sup>4</sup> represents hydrogen or an optionally substituted alkyl;
- R<sup>5</sup> represents hydrogen or an optionally substituted alkyl;
- 25 R<sup>6</sup> represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO<sub>2</sub>aryl, optionally substituted SO<sub>2</sub>alkyl, optionally substituted SO<sub>2</sub>heteroaryl, CN, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>aryl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>heteroaryl or COR<sup>7</sup>;
- R<sup>7</sup> represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;
- 30 R<sup>8</sup> and R<sup>9</sup> each independently represents hydrogen, chloro, fluoro, CF<sub>3</sub>, C<sub>1-3</sub>alkoxy or C<sub>1-3</sub>alkyl;
- Q<sup>a</sup> and Q<sup>b</sup> are each independently selected from hydrogen and CH<sub>3</sub>;
- wherein when A is a 6-membered ring the R<sup>1</sup> substituent and cyclopentene ring are
- 35 attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-

membered ring or bicyclic heterocyclyl group the R<sup>1</sup> substituent and cyclopentene ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other; and derivatives thereof.

- 5 2. A compound according to claim 1 wherein B is pyridyl.
3. A compound according to claim 1 which is a compound of formula (IA):



(IA)

- 10 wherein:  
 W, X, and Y each represent CR<sup>12</sup> or N;  
 V represents CR<sup>1</sup>, CR<sup>12</sup> or N;  
 wherein at least two of W, X, Y and V is CR<sup>12</sup>, and R<sup>12</sup> is independently selected from  
 hydrogen, halogen, CF<sub>3</sub>, CH<sub>3</sub>, NH<sub>2</sub>, NHC<sub>1-6</sub>alkyl, NHCOC<sub>1-6</sub>alkyl, and SCH<sub>3</sub>;  
 15 Q<sup>1</sup> and Q<sup>2</sup> each represents CH, or one of Q<sup>1</sup> and Q<sup>2</sup> is N and the other is CH;  
 R<sup>1</sup> is CO<sub>2</sub>H, CONR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>CO<sub>2</sub>H, SO<sub>2</sub>C<sub>1-6</sub>alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>CONR<sup>5</sup>R<sup>6</sup>, tetrazolyl or  
 COSO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>;  
 R<sup>2a</sup> and R<sup>2b</sup> are selected from hydrogen, halogen, optionally substituted C<sub>1-6</sub>alkyl, and  
 optionally substituted C<sub>1-6</sub>alkoxy;  
 20 R<sup>x</sup> represents optionally substituted C<sub>3-8</sub>alkyl, optionally substituted C<sub>3-8</sub>alkenyl, and  
 optionally substituted CH<sub>2</sub>phenyl;  
 R<sup>5</sup> is hydrogen or C<sub>1-4</sub>alkyl;  
 R<sup>6</sup> is hydrogen, C<sub>1-4</sub>alkyl or SO<sub>2</sub>phenyl;  
 R<sup>12</sup> is selected from hydrogen, halogen, NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>COC<sub>1-6</sub>alkyl, NR<sup>5</sup>SO<sub>2</sub>C<sub>1-6</sub>alkyl, OR<sup>5</sup>,  
 25 SR<sup>5</sup>, and optionally substituted C<sub>1-6</sub>alkyl;  
 or derivatives thereof.

4. A compound according to claim 3 wherein one of Q<sup>1</sup> and Q<sup>2</sup> is N and the other is  
 CH.
- 30 5. A compound according to claim 1 selected from the compounds of Examples 1 to  
 417 and derivatives thereof.
6. A compound according to any one of claims 1 to 5 selected from the compounds of  
 35 of Examples 145-148, 213-241, 342-368, and 388-417 and derivatives thereof.

7. A pharmaceutical composition comprising a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.
- 5 8. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.
9. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
- 10 10. A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.
- 15 11. A method of treating a human or animal subject suffering from a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder, which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.
- 20 12. A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to any one of claims 1 to 6 or a pharmaceutically acceptable derivative thereof.
- 25 13. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
- 30 14. Use of a compound according to any one of claims 1 to 4 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as a pain, inflammatory, immunological, bone, neurodegenerative or renal disorder.
- 35 15. Use of a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment or prevention of a condition such as inflammatory pain, neuropathic pain or visceral pain.